危急疾病中的IGFBP-2:生长激素/胰岛素类生长因子轴中的预后标志物
Christos Savvidis1, Eleni Kouroglou1, Efthymia Kallistrou1
1Department of Endocrinology, Hippokration Hospital, 11527 Athens, Greece.
概括
危急疾病会增加胰岛素样生长因子结合蛋白2 (IGFBP-2),影响生长激素 (GH) 和胰岛素样生长因子 (IGF) 的动态. 这种升高可能作为疾病严重程度和结果的预后标志物.
科学领域:
- 内分泌学 在内分泌学.
- 关键护理医学 关键护理医学
- 生物化学 生物化学
背景情况:
- 危急疾病 (CI) 破坏生长激素 (GH) /胰岛素类生长因子 (IGF) 轴,改变胰岛素类生长因子结合蛋白 (IGFBPs).
- 在CI期间,胰岛素类生长因子结合蛋白2 (IGFBP-2) 持续升高,与IGF-1,IGFBP-3和酸可变子单元 (ALS) 反向相关.
研究的目的:
- 调查IGFBP-2在严重疾病期间的作用和临床意义.
- 探索IGFBP-2作为CI中的预后和诊断标记物的潜力.
主要方法:
- 在患有严重疾病的患者中分析IGFBP-2水平.
- IGFBP-2水平与疾病严重程度标志物和患者结局的相关性.
- 对IGFBP-2在CI期间对内分泌,代谢和炎症途径的参与进行现有研究的审查.
主要成果:
- 在CI期间IGFBP-2的持续升高,由细胞因子活性驱动,而不是直接的GH/IGF轴调节失调.
- IGFBP-2的升高与IGF-1,IGFBP-3和ALS相反相关.
- 高水平的IGFBP-2与增加的死亡率和更长的住院时间有关,并且与对照组相比,在败血症和COVID-19中明显高.
结论:
- 在CI期间IGFBP-2升高是一种具有显著临床影响的适应性反应.
- IGFBP-2显示出作为疾病严重程度和患者结果的预后标记物的潜力.
- 血IGFBP-2测量可以在评估CI时提供诊断实用性,特别是当传统生物标志物不能确定时.
相关概念视频
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Role of Hematopoietic Growth Factors
1.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
1.2K
Hypoglycemia and Glucagon
152
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
152
PI3K/mTOR/AKT Signaling Pathway
3.4K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.4K


